Premium
(MM) (PCYC)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Ibrutinib (IMBRUVICA®) Phase Ib/II Data Show Promise in Patients with Chronic Graft-Versus-Host-Disease Data presented today at the American Society of Clinical Oncology Annual Meeting - This...
Phase III HELIOS Study Results Show Ibrutinib (IMBRUVICA®) Combination Therapy Significantly Increased Progression-Free Survival in Previously-Treated Chronic Lymphocytic Leukemia/Small...
Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Study Commences for Patients with Two Relapsed/Refractory Blood Cancers PR Newswire SUNNYVALE, Calif., May 28, 2015...
European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA® (ibrutinib) to Treat Waldenstrom's Macroglobulinemia Would Become First EMA-approved Therapy for Patients...
New ibrutinib (IMBRUVICA®) Data to be Showcased at American Society of Clinical Oncology (ASCO) Annual Meeting IMBRUVICA Combination Data in Chronic Lymphocytic Leukemia to be Featured in...
Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates PR Newswire SUNNYVALE, Calif., May 1, 2015 SUNNYVALE, Calif., May 1, 2015 /PRNewswire/ -- Pharmacyclics...
Ibrutinib (IMBRUVICA®) Improves Outcomes for Pancreatic Ductal Adenocarcinoma in Mouse Models - Note: This press release corresponds to abstract 396 PR Newswire PHILADELPHIA, April 20, 2015...
IMBRUVICA® (ibrutinib) Longer-Term Follow-Up Data Demonstrate Durable Responses, Including Complete Responses, in Patients with Chronic Lymphocytic Leukemia (CLL) Oral Presentation at the...
New Longer-Term IMBRUVICA® (ibrutinib) Data Show High Response Rates in Patients with Waldenstrom's Macroglobulinemia Data Published in The New England Journal of Medicine Show 91% Overall...
Solid Tumor Study Investigating Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Commences in Patients with Relapsed/Refractory Non-Small Cell Lung, Breast and Pancreatic...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
